Dr. Eric Devroe has served as Acrivon's Chief Operating Officer since August 2022, having joined as Senior Vice President, Business Operations in October 2020, and served as Corporate Secretary from January 2021 to December 2022. He is a life-science executive and entrepreneur who was previously Founder and CEO of Xione Therapeutics, an oncology spin-out of MD Anderson Cancer Center, Strategic Advisor for Therapeutics Discovery at MD Anderson, and Founder and CEO of Opsonix, an infectious-disease spin-out of Harvard's Wyss Institute. Earlier he was VP, Business & Strategy Development at Metamark Genetics and an associate at Flagship Pioneering. Dr. Devroe received a B.S. in microbiology from the University of Texas at Austin and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University.